3.51
price up icon2.33%   0.08
after-market Dopo l'orario di chiusura: 3.49 -0.02 -0.57%
loading

Perché le azioni Aclaris Therapeutics Inc (ACRS) sono in ribasso?

Abbiamo notato un calo di 9.30% nelle azioni di Aclaris Therapeutics Inc (ACRS) durante la sessione di negoziazione di 2026-01-28. Sebbene ciò possa essere attribuito alla normale volatilità o a vari fattori interni ed esterni, tieni presente che stiamo monitorando attivamente la situazione e forniremo aggiornamenti tempestivi il prima possibile!
2023-11-13:

Aclaris Therapeutics Stock (ACRS) dropped by 86.44% from $4.755 to $0.6449 in the trading on Monday November 13, 2023. The reason why ACRS stock down today is due to topline results from a Phase 2b study of zunsemetinib (ATI-450) in subjects with moderate to severe rheumatoid arthritis.

  • Citing topline data at 12 weeks, patients who received either 20mg or 50mg doses of oral zunsemetinib didn’t meet the main endpoint called ACR20 or any secondary endpoints.
  • Based on the overall program results, Aclaris will discontinue further development of the ATI-450 program, including halting enrollment of Aclaris' ongoing Phase 2a trial of zunsemetinib in psoriatic arthritis.
$96.95
price down icon 1.27%
$100.07
price down icon 1.00%
$32.63
price down icon 2.16%
$113.75
price down icon 2.59%
$156.87
price down icon 0.60%
biotechnology ONC
$340.38
price down icon 2.75%
Capitalizzazione:     |  Volume (24 ore):